☰

Sreyashi Basu, Ph.D. - Publications

Affiliations: 
2000 University of Connecticut, Storrs, CT, United States 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, et al. mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine. 12. PMID 32554706 DOI: 10.1126/Scitranslmed.Abc4220  0.326
2019 Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine. PMID 31873309 DOI: 10.1038/S41591-019-0694-X  0.401
2019 Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, ... Basu S, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. The Lancet. Haematology. PMID 31400961 DOI: 10.1016/S2352-3026(19)30114-0  0.319
2019 Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, ... ... Basu S, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30635425 DOI: 10.1073/Pnas.1811067116  0.379
2019 Gao J, Siefker-Radtke AO, Navai N, Campbell MT, Slack Tidwell R, Guo C, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Blando JM, Vence LM, Duan F, Basu S, et al. A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). Journal of Clinical Oncology. 37: 4551-4551. DOI: 10.1200/Jco.2019.37.15_Suppl.4551  0.312
2019 Daver NG, Garcia-Manero G, Konopleva MY, Alfayez M, Pemmaraju N, Kadia TM, DiNardo CD, Cortes JE, Ravandi F, Abbas H, Basu S, Jabbour E, Pierce SA, Estrov ZE, Takahashi K, et al. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study Blood. 134: 830-830. DOI: 10.1182/Blood-2019-131494  0.338
2019 An X, Adolacion JR, Alfayez M, Matthews J, Flores W, Kornblau SM, Saeedi A, Basu S, Daver NG, Varadarajan N. Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML Blood. 134: 1950-1950. DOI: 10.1182/Blood-2019-122081  0.408
2019 Daver N, Kantarjian H, Mackay S, Flynn B, Basu S, Garcia-Manero G, Alfayez M, Konopleva M, Matthews J, Kornblau S, Jabbour E, Zhou J, Andreeff M. Abstract LB-222: Polyfunctionality determined by single-cell proteomics of bone marrow-derived CD4 T cells from patients with acute myeloid leukemia identifies patients responding to anti-PD-1-based therapy and discovers profound T cell defect in mutant TP53 disease Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-222  0.399
2019 Campbell M, Martin S, Tam A, Sheth R, Singh S, Ahrar K, Slack Tidwell B, Rao P, Karam J, Wood C, Tannir N, Jonasch E, Gao J, Shah A, Blando J, ... ... Basu S, et al. A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC) Annals of Oncology. 30: v389-v390. DOI: 10.1093/Annonc/Mdz249.059  0.339
2018 Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. PMID 30500073 DOI: 10.1002/Cncr.31896  0.36
2018 Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nature Medicine. 24: 123-124. PMID 29414936 DOI: 10.1038/Nm.4489  0.347
2018 Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Lopez JH, Kornblau S, Andreeff M, Bueso-Ramos CE, Blando JM, et al. Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. Journal of Clinical Oncology. 36: 7016-7016. DOI: 10.1200/Jco.2018.36.15_Suppl.7016  0.359
2018 Jain N, Ferrajoli A, Basu S, Thompson PA, Burger JA, Kadia TM, Estrov ZE, Pemmaraju N, Lopez W, Thakral B, Khoury JD, Bueso-Ramos CE, Blando J, O'Brien SM, Kantarjian HM, et al. A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation Blood. 132: 296-296. DOI: 10.1182/Blood-2018-99-120355  0.3
2018 Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Kadia TM, Konopleva MY, Jabbour EJ, DiNardo CD, Assi R, Pierce SA, Alvarado Y, Estrov ZE, Pemmaraju N, Takahashi K, et al. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study Blood. 132: 906-906. DOI: 10.1182/Blood-2018-99-120157  0.361
2018 Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia TM, Alvarado Y, Jabbour EJ, Konopleva MY, Takahashi K, Kornblau SM, DiNardo CD, Estrov ZE, ... ... Basu S, et al. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Blood. 132: 905-905. DOI: 10.1182/Blood-2018-99-116078  0.404
2017 Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, Srivastava PK. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proceedings of the National Academy of Sciences of the United States of America. PMID 28439004 DOI: 10.1073/Pnas.1612177114  0.342
2017 Daver NG, Garcia-Manero G, Cortes JE, Basu S, Ravandi F, Kadia TM, Borthakur G, Jabbour E, Dinardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreeff M, et al. Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. Journal of Clinical Oncology. 35: e18505-e18505. DOI: 10.1200/Jco.2017.35.15_Suppl.E18505  0.35
2017 Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia TM, et al. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. Journal of Clinical Oncology. 35: 7026-7026. DOI: 10.1200/Jco.2017.35.15_Suppl.7026  0.39
2017 Reilley M, Basu S, Katkhuda R, Patterson N, Chen T, Blando JM, Menter D, Maru DM, Allison JP, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. Journal of Clinical Oncology. 35: 3574-3574. DOI: 10.1200/Jco.2017.35.15_Suppl.3574  0.362
2017 Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu PC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, ... ... Basu S, et al. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia Blood. 130: 815-815. DOI: 10.1182/Blood.V130.Suppl_1.815.815  0.415
2017 Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Lopez JH, Kornblau S, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, et al. Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity Blood. 130: 185-185. DOI: 10.1182/Blood.V130.Suppl_1.185.185  0.443
2017 Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, et al. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML Blood. 130: 1345-1345. DOI: 10.1182/Blood.V130.Suppl_1.1345.1345  0.403
2017 Gao J, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campell M, Ng CS, Slack RS, Rao P, Allison JP, Blando JM, Vence LM, Basu S, et al. Abstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct083  0.37
2016 Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, et al. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) Blood. 128: 763-763. DOI: 10.1182/Blood.V128.22.763.763  0.417
2016 Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O'Brien SM, et al. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial Blood. 128: 59-59. DOI: 10.1182/Blood.V128.22.59.59  0.38
2016 Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Juliana L, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, et al. Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML) Blood. 128: 2900-2900. DOI: 10.1182/Blood.V128.22.2900.2900  0.441
2016 Jain N, Basu S, Thakral B, Burger J, Thompson PA, Ferrajoli A, Estrov Z, Bueso-Ramos CE, Stingo F, Bassett RL, Daver N, Kadia TM, Matthews J, Flores W, Somani N, et al. Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL) Blood. 128: 2012-2012. DOI: 10.1182/Blood.V128.22.2012.2012  0.418
2016 Daver N, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Kornblau S, Konopleva M, Andreeff M, Borthakur G, Jain N, Wierda W, Verstovsek S, Ruvolo P, Kadia T, Matthews J, et al. Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML) Cancer Research. 76: 3205-3205. DOI: 10.1158/1538-7445.Am2016-3205  0.396
2012 Li C, Buckwalter MR, Basu S, Garg M, Chang J, Srivastava PK. Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic information. Proceedings of the National Academy of Sciences of the United States of America. 109: 17543-8. PMID 23045695 DOI: 10.1073/Pnas.1205867109  0.328
2012 Ghosh AK, Basu S. Tumor macrophages as a target for Capsaicin mediated immunotherapy. Cancer Letters. 324: 91-7. PMID 22579786 DOI: 10.1016/J.Canlet.2012.05.002  0.304
2012 Ghosh M, McAuliffe B, Subramani J, Basu S, Shapiro LH. CD13 regulates dendritic cell cross-presentation and T cell responses by inhibiting receptor-mediated antigen uptake. Journal of Immunology (Baltimore, Md. : 1950). 188: 5489-99. PMID 22544935 DOI: 10.4049/Jimmunol.1103490  0.361
2012 Nevius E, Srivastava PK, Basu S. Oral ingestion of Capsaicin, the pungent component of chili pepper, enhances a discreet population of macrophages and confers protection from autoimmune diabetes Mucosal Immunology. 5: 76-86. PMID 22113584 DOI: 10.1038/Mi.2011.50  0.341
2012 Li C, Matthew B, Garg M, Basu S, Chang J, Srivastava P. Dendritic cells sequester antigenic epitopes or their precursors for several weeks Molecular Immunology. 51: 31-32. DOI: 10.1016/J.Molimm.2012.02.088  0.316
2007 Beltran J, Ghosh AK, Basu S. Immunotherapy of tumors with neuroimmune ligand capsaicin. Journal of Immunology (Baltimore, Md. : 1950). 178: 3260-4. PMID 17312175 DOI: 10.4049/Jimmunol.178.5.3260  0.341
2005 Basu S, Srivastava P. Immunological role of neuronal receptor vanilloid receptor 1 expressed on dendritic cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 5120-5. PMID 15793000 DOI: 10.1073/Pnas.0407780102  0.316
2004 Basu S, Matsutake T. Heat shock protein-antigen presenting cell interactions. Methods (San Diego, Calif.). 32: 38-41. PMID 14624876 DOI: 10.1016/S1046-2023(03)00189-0  0.33
2001 Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N. Primary Tumor Tissue Lysates Are Enriched in Heat Shock Proteins and Induce the Maturation of Human Dendritic Cells Journal of Immunology. 167: 4844-4852. PMID 11673488 DOI: 10.4049/Jimmunol.167.9.4844  0.347
2001 Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 14: 303-13. PMID 11290339 DOI: 10.1016/S1074-7613(01)00111-X  0.329
2001 Robert J, Ménoret A, Basu S, Cohen N, Srivastava PR. Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70. European Journal of Immunology. 31: 186-95. PMID 11265634 DOI: 10.1002/1521-4141(200101)31:1<186::Aid-Immu186>3.0.Co;2-D  0.349
2001 Basu S, Srivastava PK. Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress & Chaperones. 5: 443-51. PMID 11189450 DOI: 10.1379/1466-1268(2000)005<0443:Hsptfo>2.0.Co;2  0.357
2000 Binder RJ, Anderson KM, Basu S, Srivastava PK. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. Journal of Immunology (Baltimore, Md. : 1950). 165: 6029-35. PMID 11086034 DOI: 10.4049/Jimmunol.165.11.6029  0.324
2000 Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. International Immunology. 12: 1539-46. PMID 11058573 DOI: 10.1093/Intimm/12.11.1539  0.336
1999 Basu S, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. The Journal of Experimental Medicine. 189: 797-802. PMID 10049943 DOI: 10.1084/Jem.189.5.797  0.32
1998 Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 8: 657-65. PMID 9655479 DOI: 10.1016/S1074-7613(00)80570-1  0.386
1997 Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. The Journal of Experimental Medicine. 186: 1315-22. PMID 9334371 DOI: 10.1084/Jem.186.8.1315  0.334
Show low-probability matches.